Exhibit 99.1 Immunocore Holdings plc Unaudited Condensed Consolidated Interim Financial Statements Unaudited Condensed Consolidated Statements of Profit / (Loss) and Comprehensive (Loss) / Income Three Months Ended Nine Months Ended September 30, September 30, 2023 2022 2023 2022 Notes £’000 £’000 £’000 £’000 Product revenue, net 3 49,719 33,252 137,285 64,926 Pre-product revenue, net 3 — 3,051 — 9,588 Total revenue from sale of therapies 49,719 36,303 137,285 74,514 Collaboration revenue 3 1,769 4,896 6,50 ...